10X Fund Issues Statement on Exercise of Additional 200,000 Galectin Therapeutics Warrants

10X Fund Issues Statement on Exercise of Additional 200,000 Galectin
Therapeutics Warrants

NICEVILLE, Fla., Nov. 4, 2013 (GLOBE NEWSWIRE) -- Rod D. Martin, Co-Founder
and Managing Member of 10X Capital Management, LLC, whose 10X Fund is the
largest shareholder in Galectin Therapeutics (Nasdaq:GALT), today issued the
following statement:

"Friday, November 1st, the 10X Fund exercised warrants for another 200,000
shares in Galectin Therapeutics. These warrants were not due to expire until
2019. Including our October 10 warrant exercise, this increases our holdings
by a total of 388,000 since the first of October."

About 10X Capital Management

10X Capital Management and its biotech-focused 10X Fund were co-founded by
James C. Czirr and Rod D. Martin. The Fund, which is based in Niceville,
Florida, is especially noted for its restructuring and turnaround of Galectin
Therapeutics (Nasdaq:GALT), where Czirr serves as Executive Chairman and
Martin as Vice Chairman of the Board.

AboutGalectin Therapeutics

Galectin Therapeutics(Nasdaq:GALT) is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development expertise as
well as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear development
pathway to clinical enhancement and commercialization for our lead compounds
in liver fibrosis and cancer. Additional information is available
atwww.galectintherapeutics.com.

CONTACT: James C. Czirr
         (208) 265-0643
        
         or
        
         Rod D. Martin
         (415) 685-3488
 
Press spacebar to pause and continue. Press esc to stop.